Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US

Relief Therapeutics Holding SA / Key word(s): Miscellaneous Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US 22-Jan-2025 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US Sale of GOLIKE Rights Outside the U.S. to Nutrisens Relief to Focus on R&D of Pipeline Assets and Licensing for Commercialized Products

GENEVA (JAN. 22, 2025) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced the sale of its intellectual property and commercialization rights for GOLIKE outside the United States to Nutrisens, a leading independent platform that develops and commercializes clinical nutrition solutions for patients. This transaction completes Relief’s previously announced transition from a direct marketing and sales infrastructure to a partnership-based model, enabling the Company to optimize its cost structure and allocate resources on advancing its high-priority R&D programs.

Under the agreement, Nutrisens will take over marketing and sales activities for GOLIKE in Relief’s European markets. Relief has also transferred its existing third-party distribution agreements for GOLIKE in other regions to Nutrisens, while retaining its rights in the United States, where the product is exclusively licensed to Eton Pharmaceuticals. With its significant experience, Nutrisens will continue to support patients and health professionals with GOLIKE solutions worldwide outside the United States. Relief intends to continue to supply GOLIKE globally and complete development of certain line extensions to address patient needs.